Bladder cancer
Conditions
Interventions
Tumor group:Taking 4 ml of peripheral blood
non-tumor group:Taking 4 ml of peripheral blood
Sponsors
Shenzhen University Institute of Urology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.First-diagnosed and untreated bladder urothelial carcinoma. 2.Life expectancy is greater than 5 years and above. 3.Except for patients undergoing total cystectomy. 4.Willing to cooperate with sample collection and sustainable follow-up.
Exclusion criteria
Exclusion criteria: 1.Any of the following: immunodeficiency or damage (such as AIDS patients), immunosuppressive drugs or radiation therapy; fever and acute infectious diseases, including active tuberculosis, or receiving anti-tuberculosis treatment With severe chronic cardiovascular or cerebrovascular disease or chronic kidney disease; 2.Merging other organ tumors; 3.Those who have received chemotherapy, radiotherapy, or immunotherapy in the past 4 weeks (except for intravesical infusion chemotherapy immediately after surgery); 4.It is known or suspected that bladder perforation occurs during surgery; 5.Patients with severe urethral stricture can not be placed into the cystoscope; 6.Pelvic CT examination or full physical examination reports that the tumor has been metastasized; 7.Low immune function, congenital immunodeficiency disease, or history of organ transplantation; 8.Suffering from severe cardiovascular and cerebrovascular diseases such as myocardial infarction, severe or unstable angina pectoris, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism unable tolerate TURBT surgery; 9.There are obvious major visceral dysfunctions, such as: creatinine > 1.5 times the upper limit of the normal range, AST, ALT, total bilirubin > 1.5 times the upper limit of the normal range; 10.The body temperature of fever is over 38 °C, and there are obvious active infections that can affect clinical trials such as acute pneumonia, active tuberculosis, subjects with severe urinary tract infection, etc. 11.Patients rely on opioids or alcohol; 12.The investigator believes that there may be any situation that increases the risk of the subject or interferes with the execution of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood test;Urinalysis;Transcriptome;Urine metabolome;Methylome; | — |
Countries
China
Contacts
Public ContactSong Wu
Shenzhen University Institute of Urology
Outcome results
None listed